Michael A. White, PhD Chief Scientific Officer

Dr. White is a discovery biologist with two decades of R&D leadership experience in industry and academia. He has deep expertise in cell regulation, tissue homeostasis, tumor biology, therapeutic target discovery, technology development and drug discovery.

Prior to joining Biosplice, Dr. White was Chief Scientific Officer for Tumor Biology at Pfizer. There he led a cross-disciplinary group to build an oncology small-molecule pipeline focused on first-in-class therapies that intercept oncogenic signaling networks, modulate tumor/host interactions and promote productive anti-tumor immune responses. These efforts culminated in numerous INDs within the past four years. Previously, Dr. White held positions of Professor of Cell Biology at UT Southwestern Medical Center, Associate Director of Basic Science for the Harold Simmons Comprehensive Cancer Center, and inaugural Director of the UTSW Cancer Intervention and Prevention Discovery training program. His appointments include the Hortense and Morton Sanger Professorship in Oncology, the Sherry Wigley Crow Cancer Research Endowed Chair, and the Grant A. Dove Distinguished Chair for Research in Oncology. In 2015, Dr. White received the inaugural National Institute of Cancer’s Outstanding Investigator Award.

Dr. White’s research has focused on oncogenic Ras effector networks, the molecular architecture of mitogenic signaling pathways, functional annotation of cancer genomes and genomics-guided cancer target discovery. He has authored over 150 publications with over 22,000 citations.

Dr. White completed his postdoctoral training in cancer biology and signal transduction at Cold Spring Harbor Laboratories in New York. He received his PhD in Biology from the University of North Carolina at Chapel Hill, and his BS in Zoology from University of Iowa.

Darrin M. Beaupre, MD, PhD Chief Medical Officer, Oncology

Dr. Beaupre is a Medical Oncologist and Hematologist with 14 years of industry experience in both early and late phase clinical development.

Prior to joining Biosplice, Dr. Beaupre was the head of Early Oncology Development and Clinical Research at Pfizer where he supervised the filing and execution of numerous INDs in broad platform areas including small molecules, large molecules, antibody drug conjugates, bispecifics, a CAR-T, and vaccines. Prior to joining Pfizer, he was the Head of Early Development as well as the Immunotherapy and Non-Hodgkin’s Lymphoma Therapeutic Area head at Pharmacyclics. There he participated in the NDA filings of ibrutinib in mantle cell and marginal zone lymphoma both of which achieved accelerated approvals. He also initiated phase 2 and 3 trials testing ibrutinib in several Non-Hodgkin’s Lymphoma indications. Pre-dating this experience, Dr. Beaupre was a member of the AMGEN early development group and was a Medical Director involved in filing multiple INDs. Linked to his translational medicine background, he previously served as an Assistant Professor at the Moffit Cancer Center in the Department of Interdisciplinary Oncology. In addition to being awarded a Hollis Brownstein Research Grant, he also received a Clinical Scholars in Oncology Award from the National Cancer Institute and was nominated as “new scientist to watch” by the Leukemia Research Foundation.

Dr. Beaupre completed his Medical Oncology and Hematology Fellowship and post-doctoral research training at the University of Miami Sylvester Cancer Center, where he was supported by an NIH K12 Award. He completed his MD and PhD in Cancer Biology at the University of Texas at Houston and MD Anderson Cancer Center, respectively, where he was a member of the MD PhD program. He also received an MS degree in Biotechnology and BS degree in Biology at the University of Lowell in Lowell, Massachusetts, where he was awarded the Outstanding Graduate Student Award.